This approval marks the second international marketing authorization forsugemalimab outside of China,following its recent approval by the European Commission.
The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial,which demonstrated thatsugemalimab in combination with chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with metastatic NSCLC.
Long-term survival data from the GEMSTONE-302 study were presented at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting.
CStone is actively communicating with regulatory authorities,including the European Medicines Agency (EMA) for marketing authorization applications for additional indications of sugemalimab.
CStone has entered into a strategic commercialization partnership with Ewopharma for sugemalimab in Central & Eastern Europe and Switzerland,with further collaborations expected soon in regions including Western Europe,Latin America,the Middle East,and Southeast Asia.
SUZHOU,China,Oct. 31,2024 -- CStone Pharmaceuticals (HKEX: 2616),an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies,today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab in combination with platinum-based chemotherapy as a first-line treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) without EGFR-sensitive mutations or ALK,ROS1,RET genomic alterations. This marks the second overseas approval for sugemalimab following its recent authorization by the European Commission.
Dr. Jason Yang,CEO,President of R&D and Executive Director of the Board at CStone,said,"This approval is a significant milestone in our global expansion strategy. Sugemalimab is the first domestic anti-PD-L1 antibody to receive approval outside of China and has already entered the world's second-largest pharmaceutical market,the EU. Now,with the UK approval,sugemalimab continued to expand its presence in the European market. The long-term survival data,recently presented at this year's ESMO Congress,further confirmed sugemalimab's value in the frontline treatment landscape for metastatic NSCLC."
Dr. Yang added,"We are actively pursuing additional partnerships across Western Europe,Southeast Asia,and Canada,and expect to finalize some of these agreements shortly. Meanwhile,we are communicating with the European Medicines Agency (EMA) and other agencies for additional regulatory applications for other sugemalimab indications,including Stage III NSCLC,first-line gastric cancer,and first-line esophageal squamous cell carcinoma,aiming to bring innovative treatment options to more patients globally."
The MHRA's approval is primarily based on the data from GEMSTONE-302,a multicenter,randomized,double-blind phase 3 trial. The study demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to placebo combined with chemotherapy in treatment-naïve patients with metastatic NSCLC. Study results have been published in The Lancet Oncology and Nature Cancer,and have been presented at multiple international academic conferences in both oral and poster sessions.
About Sugemalimab
The anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat® transgenic animal platform,which allows creation of fully human antibodies in one step. Sugemalimab is a fully human,full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody,which may reduce the risk of immunogenicity and toxicity for patients,a unique advantage over similar drugs. Sugemalimab's unique molecular design enables a dual mechanism of action that not only blocks PD-1/PD-L1 interaction,but also induces antibody dependent cellular phagocytosis (ADCP) by cross-linking PD-L1 expressing tumor cells with tumor associated macrophages (TAMs) without harming Effector T-cells. This differentiation has resulted in potentially best-in-class efficacy/safety across a variety of tumor types.
The National Medical Products Administration (NMPA) of China has approved sugemalimab for five indications:
In combination with chemotherapy as first-line treatment of patients with metastaticsquamous and non-squamous NSCLC;
For the treatment of patients withunresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy;
For the treatment of patients with relapsed or refractoryextranodal NK/T-cell lymphoma;
In combination withfluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced,recurrent or metastatic ESCC; and
In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment forunresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with a PD-L1 expression (Combined Positive Score [CPS] ≥5).
The European Commission (EC) has approved sugemalimab (brand name: Cejemly®) in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitising EGFR mutations,or ALK,ROS1 or RET genomic tumor aberrations.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has approved the marketing authorization application for sugemalimab in combination with platinum-based chemotherapy for first-line treatment of metastatic NSCLC with no sensitising EGFR mutations,ROS1 or RET genomic tumor aberrations.
About CStone
CStone (HKEX: 2616),established in late 2015,is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients' unmet medical needs in China and globally,the Company has made significant strides since its inception. To date,the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company's pipeline is balanced by 16 promising candidates,featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs),multispecific antibodies,immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum,from preclinical and translational research to clinical development,drug manufacturing,business development,and commercialization.
For more information about CStone,please visit www.cstonepharma.com.
IR contact: ir@cstonepharma.com
PR contact: pr@cstonepharma.com
Forward-looking statements
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law,we undertake no obligation to update or publicly revise any forward-looking statements,whether as a result of new information,future events or otherwise,after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.